Area of research
Oncology · Molecular Biology
Research interest
Research interests include Cancer Cells and Metastasis, RNA modifications and cancer, Cancer Immunotherapy and Biomarkers, and Immunotherapy and Immune Responses.
Epigenetic imprinting bridges infection and lung cancer.
TNF-⍺-mediated myeloid-instructed CD14<sup>+</sup>CD4<sup>+</sup> T cells are associated with poor survival in lung adenocarcinoma.
jazzPanda: A hybrid approach to find spatial marker genes in imaging-based spatial transcriptomics data
Benchmarking long-read RNA-sequencing technologies with
<i>LongBench:</i>
a cross-platform reference dataset profiling cancer cell lines with bulk and single-cell approaches
Effects of CVA21, an Oncolytic Virus, in Combination with Pembrolizumab on Immunogenicity and the Tumor Microenvironment in Advanced NSCLC: A Phase I/II Trial.
Mapping lung cancer ventilation dynamics using functional imaging and lung mechanics.
Non-apoptotic caspase-8 is critical for orchestrating exaggerated inflammation during severe SARS-CoV-2 infection.
Repurposing BH3 mimetics to deplete tumour-infiltrating regulatory T cells and enhance anti-tumour immunity in non-small cell lung cancer
Supplementary Table S5 from Effects of CVA21, an Oncolytic Virus, in Combination with Pembrolizumab on Immunogenicity and the Tumor Microenvironment in Advanced NSCLC: A Phase I/II Trial
Supplementary Figure S3 from Effects of CVA21, an Oncolytic Virus, in Combination with Pembrolizumab on Immunogenicity and the Tumor Microenvironment in Advanced NSCLC: A Phase I/II Trial
Supplementary Figure S5 from Effects of CVA21, an Oncolytic Virus, in Combination with Pembrolizumab on Immunogenicity and the Tumor Microenvironment in Advanced NSCLC: A Phase I/II Trial
Supplementary Table S3 from Effects of CVA21, an Oncolytic Virus, in Combination with Pembrolizumab on Immunogenicity and the Tumor Microenvironment in Advanced NSCLC: A Phase I/II Trial
Data from Effects of CVA21, an Oncolytic Virus, in Combination with Pembrolizumab on Immunogenicity and the Tumor Microenvironment in Advanced NSCLC: A Phase I/II Trial
Supplementary Figure S1 from Effects of CVA21, an Oncolytic Virus, in Combination with Pembrolizumab on Immunogenicity and the Tumor Microenvironment in Advanced NSCLC: A Phase I/II Trial
Supplementary Table S4 from Effects of CVA21, an Oncolytic Virus, in Combination with Pembrolizumab on Immunogenicity and the Tumor Microenvironment in Advanced NSCLC: A Phase I/II Trial
Supplementary Table S1 from Effects of CVA21, an Oncolytic Virus, in Combination with Pembrolizumab on Immunogenicity and the Tumor Microenvironment in Advanced NSCLC: A Phase I/II Trial
Supplementary Figure S2 from Effects of CVA21, an Oncolytic Virus, in Combination with Pembrolizumab on Immunogenicity and the Tumor Microenvironment in Advanced NSCLC: A Phase I/II Trial
Mapping Lung Cancer Ventilation Dynamics: A Pilot Mouse Study Using Functional Imaging and Lung Mechanics
Supplementary Table S2 from Effects of CVA21, an Oncolytic Virus, in Combination with Pembrolizumab on Immunogenicity and the Tumor Microenvironment in Advanced NSCLC: A Phase I/II Trial
Supplementary Figure S4 from Effects of CVA21, an Oncolytic Virus, in Combination with Pembrolizumab on Immunogenicity and the Tumor Microenvironment in Advanced NSCLC: A Phase I/II Trial
Transcriptional Dosage of Oncogenic KRAS Drives Lung Adenocarcinoma Cell States, Progression and Metastasis
TNF⍰-mediated myeloid-instructed CD14 <sup>+</sup> CD4 <sup>+</sup> T cells within the tumor microenvironment are associated with poor survival in non-small cell lung cancer
Early immune pressure initiated by tissue-resident memory T cells sculpts tumor evolution in non-small cell lung cancer.
Somatic rearrangements causing oncogenic ectodomain deletions of FGFR1 in squamous cell lung cancer
Using random forests to uncover the predictive power of distance–varying cell interactions in tumor microenvironments
Activation of KrasG12D in Subset of Alveolar Type II Cells Enhances Cellular Plasticity in Lung Adenocarcinoma.
Table S5 from Immune Surveillance in Clinical Regression of Preinvasive Squamous Cell Lung Cancer
Table S1 from Immune Surveillance in Clinical Regression of Preinvasive Squamous Cell Lung Cancer
Table S2 from Immune Surveillance in Clinical Regression of Preinvasive Squamous Cell Lung Cancer
Data from Activation of Kras<sup>G12D</sup> in Subset of Alveolar Type II Cells Enhances Cellular Plasticity in Lung Adenocarcinoma